🔓 Unlock the full profile of Chad Robins (Adaptive Biotechnologies Corp.), including verified contact details, financial insights, and professional associations.
See Chad Robins Full ProfileBelow are the ✅ Verified Contact Details to help you connect directly:
Email: cha*****@ada******.com
Mobile: 61656*****
Estimated Net Worth 💰 : ₹0 – ₹500+ Cr (approx. $0 – $60M)
Key Insights You Should Know About This Individual
- Chad Robins is the CEO and Co-Founder of Adaptive Biotechnologies Corp., which was founded in 2009 and focuses on the intersection of the immune system and diseases, particularly in developing innovative diagnostic tools and therapeutics.
- Under Chad's leadership, Adaptive Biotechnologies went public on the NASDAQ under the symbol 'ADPT', achieving a market capitalization of approximately $1.4 billion.
- The organization has made significant advancements in next-generation sequencing technologies and their applications in immunology, enabling personalized medicine approaches for various diseases, including cancer.
- Chad serves as Chairman of AltPep, which specializes in developing therapeutic approaches to neurodegenerative diseases, showcasing a commitment to tackling complex medical challenges.
- In addition to current roles, Chad has previously held the position of Lead Independent Director at HeadLight, where strategic leadership was emphasized in the evolving technology sector.
- Chad's involvement with The Coalition for 21st Century Medicine as a Board Director illustrates a dedication to advancing the future of healthcare through innovative interdisciplinary collaborations.
- Starting in 2024, Chad will assume the role of Board Chair at Life Science Washington, further demonstrating commitment to fostering growth and collaboration in the life sciences industry.
- Prior to establishing Adaptive Biotechnologies, Chad held various leadership positions, including President & COO at Connaught Real Estate Finance, which contributed to a diverse skill set in corporate management and strategic growth.